The buyout of one biotechnology company can sometimes hurt the shares of its competitors, as investors may feel like they picked the wrong merger candidate. But not in the case for those who bought ...
LONDON (Reuters) -Swiss drugmaker Novartis on Monday defended its $12 billion deal to acquire Avidity Biosciences ahead of the U.S. firm getting late-stage data for its muscle disorder treatment next ...
Swiss drugmaker Novartis on Sunday said it agreed to acquire U.S. biotech firm Avidity Biosciences for about $12 billion in cash, as the company looks to bolster its portfolio of treatments for rare ...
The purchasing party is global pharmaceutical company Novartis, which on Sunday divulged that it and Avidity had agreed to the acquisition. Under its terms, Switzerland-based Novartis will pay $72 per ...
Swiss drugmaker Novartis on Sunday said it agreed to acquire U.S. biotech firm Avidity Biosciences for about $12 billion in cash, as the company looks to bolster its portfolio of treatments for rare ...
A big premium paid to acquire Avidity Biosciences is bolstering the merger case for Dyne Therapeutics, analyst says Dyne Therapeutics' stock sees record rally, but one analyst says it could still ...
It is being acquired for quite a meaty premium. The buyer is a top name in the global pharmaceuticals space. The purchasing party is global pharmaceutical company Novartis, which on Sunday divulged ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results